Tariman Joseph D
Department of Medicine's Division of Hematology/Oncology, Northwestern University Medical Faculty Foundation, Chicago, IL, USA.
Clin J Oncol Nurs. 2007 Aug;11(4):569-74. doi: 10.1188/07.CJON.569-574.
Lenalidomide is a potent, novel thalidomide analog that has demonstrated promising clinical activity in patients with relapsed or refractory multiple myeloma (MM). It is a lead immunomodulatory drug currently approved by the U.S. Food and Drug Administration. Neutropenia, thrombocytopenia, and thromboembolic events are common adverse effects associated with lenalidomide therapy in patients with MM. Careful monitoring of those known serious adverse effects is essential to prevent life-threatening complications. This article discusses lenalidomide's mechanisms of action, clinical trial results, and the management of common adverse effects in patients with MM.
来那度胺是一种强效的新型沙利度胺类似物，已在复发或难治性多发性骨髓瘤（MM）患者中显示出有前景的临床活性。它是一种主要的免疫调节药物，目前已获美国食品药品监督管理局批准。中性粒细胞减少、血小板减少和血栓栓塞事件是MM患者接受来那度胺治疗常见的不良反应。仔细监测这些已知的严重不良反应对于预防危及生命的并发症至关重要。本文讨论了来那度胺的作用机制、临床试验结果以及MM患者常见不良反应的管理。
